TSHA Taysha Gene Therapies, Inc.
USHealthcareAs of 2026-07-08 16:00
Why TSHA matters now
Taysha Gene Therapies, Inc. (TSHA) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.49 with -0.15% on the session and $1.62B in market capitalization; recent performance reads 1-month +23.70% and YTD +16.73%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-42.4M, and EPS of $-0.12. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -7.2%.
The latest indexable market news headline is "Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potential" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $12.00; recent insider activity includes Sepp-Lorenzino Laura filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
11.11
P/S
215.02
EV/EBITDA
-10.44
DCF Value
$0.62
FCF Yield
-7.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
88.2%
Operating Margin
-1774.4%
Net Margin
-1738.4%
ROE
-56.1%
ROA
-43.2%
ROIC
-47.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-42.4M | $-0.12 |
| Q4 2025 | $5.5M | $-27.9M | $-0.08 |
| FY 2025 | $9.8M | $-109.0M | $-0.34 |
| Q3 2025 | $0.00 | $-32.7M | $-0.09 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$11.00 - $13.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.18
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.